JAZZ PHARMACEUTICAL (J7Z BE) stock market data APIs
€92.4299
0(0%)
as of July 4, 2025
Try our APIs with
free plan!
JAZZ PHARMACEUTICAL Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for J7Z.BE.
Prev. Close
92.4299
Open
92.4299
High
92.4299
Low
92.4299
52 wk Range
86.72-136.6
Market Cap
6 680 M
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get JAZZ PHARMACEUTICAL data using free add-ons & libraries
Get JAZZ PHARMACEUTICAL Fundamental Data
JAZZ PHARMACEUTICAL Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
JAZZ PHARMACEUTICAL News
New
One Jazz Pharmaceuticals Insider Raised Their Stake In The Previous Year
Viewing insider transactions for Jazz Pharmaceuticals plc's (NASDAQ:JAZZ ) over the last year, we see that insiders were net buyers. This means that a larger number of shares were purchased by insider...
Jazz Pharmaceuticals Gets UBS Buy Rating After Strong ASCO 2025 Trial Results
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 3, UBS reiterated its Buy rating on Jazz Pharmaceuticals plc (NA...
Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
– Conditional approval based on positive results from the HERIZON-BTC-01 Phase 2b trial – DUBLIN, July 1, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Eur...
The 5 Most Interesting Analyst Questions From Jazz Pharmaceuticals’s Q1 Earnings Call
Jazz Pharmaceuticals faced a challenging first quarter as revenue remained flat year over year, missing Wall Street expectations. Management attributed the performance to contrasting trends across its...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
